The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Open accessAbstract
BACKGROUND: Antipsychotic-induced metabolic side effects are major concerns in psychopharmacology and clinical psychiatry. Their pathogenetic mechanisms are still not elucidated. METHODS: Herein, we review the impact of neurotransmitters on metabolic regulation, providing insights into antipsychotic-induced metabolic side effects. RESULTS: Antipsychotic drugs seem to interfere with feeding behaviors and energy balance, processes that control metabolic regulation. Reward and energy balance centers in central nervous system constitute the central level of metabolic regulation. The peripheral level consists of skeletal muscles, the liver, the pancreas, the adipose tissue and neuroendocrine connections. Neurotransmitter receptors have crucial roles in metabolic regulation and they are also targets of antipsychotic drugs. Interaction of antipsychotics with neurotransmitters could have both protective and harmful effects on metabolism. CONCLUSION: Emerging evidence suggests that antipsychotics have different liabilities to induce obesity, diabetes and dyslipidemia. However this diversity cannot be explained merely by drugs'pharmacodynamic profiles, highlighting the need for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 2×
“comparisons of antipsychotic drugs have provided insights into the differential risk of weight gain induction and glucose and lipid handling disruption [4, 12, 14-18] (see ‘risk’ section in Table 1).”
BackgroundSelf-citationDE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 4×
“comparisons of antipsychotic drugs have provided insights into the differential risk of weight gain induction and glucose and lipid handling disruption [4, 12, 14-18] (see ‘risk’ section in Table 1).”
BackgroundInfluentialAutomated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820 · cited 1×
“comparisons of antipsychotic drugs have provided insights into the differential risk of weight gain induction and glucose and lipid handling disruption [4, 12, 14-18] (see ‘risk’ section in Table 1).”
BackgroundAlmost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome
Thorp, A. A., & Schlaich, M. P. (2015) · Journal of Diabetes Research · doi:10.1155/2015/341583 · Cited by 425 · cited 2×
“Despite the possible protective effects of beta receptor signaling, sustained sympathetic hyperactivity seems to disrupt beta receptor density and function [121].”
BackgroundPaulmann, N., Grohmann, M., Voigt, J.-P., Bert, B., Vowinckel, J., Bader, M., Skelin, M., Jevšek, M., Fink, H., Rupnik, M., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000229 · Cited by 404
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372
Cited by
Dopamine in Parkinson's disease
Latif, S., Jahangeer, M., Maknoon Razia, D., Ashiq, M., Ghaffar, A., Akram, M., El Allam, A., Bouyahya, A., Garipova, L., Ali Shariati, M., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.08.009 · Cited by 340
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Robinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73
Wang, D., Schneider-Thoma, J., Siafis, S., Burschinski, A., Dong, S., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad089 · Cited by 29
Self-citation
Metadata
- Authors
- Siafis, S., Tzachanis, D., Samara, M., & Papazisis, G.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2018-08-21
- Volume
- 16
- Issue
- 8
- Pages
- 1210-1223
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2726548756
- Cited by
- 185
- References
- 18
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. https://app.cochat.ai/papers/10.2174/1570159x15666170630163616
- The paper
- Siafis, S., Tzachanis, D., Samara, M., & Papazisis, G. (2018). Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Current Neuropharmacology. https://doi.org/10.2174/1570159x15666170630163616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.